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Abstract
The pathobiology of common diseases is influenced by heterogeneous factors interacting in complex networks.
CIDeR http://mips.helmholtz-muenchen.de/cider/ is a publicly available, manually curated, integrative database of
metabolic and neurological disorders. The resource provides structured information on 18,813 experimentally
validated interactions between molecules, bioprocesses and environmental factors extracted from the scientific
literature. Systematic annotation and interactive graphical representation of disease networks make CIDeR a
versatile knowledge base for biologists, analysis of large-scale data and systems biology approaches.
Rationale
Complex diseases such as diabetes and Alzheimer’s dis-
ease are increasingly important causes of illness and mor-
tality burden, and they are leading drivers of healthcare
costs, constituting an important burden for societies in
both developed and developing countries around the
world. It is projected that by 2025 there will be 380 mil-
lion people with type 2 diabetes world-wide [1]. Thus,
elucidating the genetic and non-genetic determinants of
complex human diseases represents one of the principal
challenges of biomedical research. In the course of the
last decades advances in our understanding of pathobio-
logical processes in complex diseases were mainly driven
by individual experiments dedicated to particular aspects
of the individual diseases. It could be shown that a dis-
ease phenotype is the result of pathobiological processes
that interact in complex networks. Members in these net-
works consist of various types of interacting biomolecules
involved in bioprocesses influenced by genetic and envir-
onmental factors. Analyses of the multiple types of inter-
connections between these factors are performed in
systems biology approaches and have also been coined
‘network medicine’ [2].
In recent years, technical advances in high-throughput
SNP analyses laid the foundation for genome-wide
association studies. Despite the success of genome-wide
association studies in identifying loci associated with
common diseases, a substantial proportion of the causal-
ity remains unexplained [3]. In a recent study, a net-
work-based approach has been used successfully to
identify interconnections between candidate genes that
were identified in a deep sequencing approach for reces-
sive cognitive disorders [4].
However, there is a lack of disease-related resources
that allow analysis of disease-associated factors integrated
in a network structure. Available disease diagrams as pro-
vided by the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [5] and using the CellDesigner software [6] allow
obtaining a broad outline about basic disease concepts
but are not designed as comprehensive resources. Here,
we present CIDeR, a database with manually curated
information from neurological and metabolic diseases.
CIDeR has been developed to facilitate systems-level ana-
lyses for providing better insight into the complex
networks of pathways and interactions that govern patho-
biological processes in human diseases. Multiple search
options and interactive graphical presentation of net-
works (Figure 1) enable inspection of the manifold inter-
relations between heterogeneous disease factors that are
required for the understanding of disease etiology.
Manual curation of interactions in disease
processes
CIDeR covers disease-related interactions from neurode-
generative diseases (Alzheimer’s disease, Parkinson’s
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disease, amyotrophic lateral sclerosis (ALS)), mental dis-
orders (schizophrenia, depression) as well as the meta-
bolic diseases (type 2 diabetes). Most of our current
knowledge about disease processes has been generated
by numerous individual experiments shedding light on
certain aspects of a disease. The results of these studies
describe interactions between entities such as proteins
but also, for example, the influence of an external sti-
mulus on protein expression or the influence of cellular
compounds on bioprocesses. An interaction is defined
as the relation between two objects (proteins, chemical
compounds, and so on) that affect each other or change
each other (for example, by activation, modification or
binding). The vast amount of experimental findings is
hidden in the textual information of the biomedical lit-
erature. Existing thesauri for proteins and chemical com-
pounds support searches in resources like PubMed [7] or
using text-mining approaches [8]. However, heteroge-
neous and ambiguous descriptions in areas like cellular
processes or phenotypes hamper the detection and pro-
cessing of published information [8]. To enable informa-
tion extraction from the biomedical publications
comprehensively and with high-quality the complete
database content of CIDeR has been generated by experi-
enced biocurators who read and manually curate the
complete articles from peer-reviewed scientific literature.
For the selection of appropriate articles we make use of
automated text mining [9], searches in PubMed and
information from referenced literature. The approach of
annotating diseases in CIDeR is to collect information of
disease processes that is required to describe the current
knowledge of the pathobiology of common diseases. The
process-oriented strategy allows assembling the intercon-
nections between various disease factors into integrated
networks. Using manual curation enables translation of
complicated topics into established vocabularies to pro-
vide information for further analysis. It is, for example,
not apparent that the ‘Morris water maze task’ is used to
test spatial learning and memory of mammalian model
organisms [10]. Manual curation allows annotating
respective results by using the Gene Ontology terms
‘GO:0008542: visual learning’ and ‘GO:0007613: memory’.
Furthermore, detailed manual curation permitted us to
richly annotate the interactions and to place them in
their relevant context. This contextual annotation
includes details like the species used in the experiments,
gender, use of model organisms, supporting publication,
cell type, cell-line, tissue, and other aspects. As of May
2012, we have reviewed 1,912 publications and curated
18,813 disease-relevant interactions (Figure 2).
Figure 1 Graphical presentation of a lithium interaction network in CIDeR. The graph shows the interaction network of lithium in bipolar
disorder and amyotrophic lateral sclerosis together with functional interactions between proteins (beige), chemical compounds (green), cell
types (light blue) and biological processes (orange). To the left, a pop-up window is open that shows detailed curated information related to the
interaction between ‘3-Methyladenine’ and ‘motor neuron degeneration’. CALR, calreticulin; SOD, superoxide dismutade.
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Data structure of disease interactions
For transformation of the biomedical information into a
data structure suitable for bioinformatics applications as
well as for wet lab scientists, interactions in CIDeR con-
sist of three parts (Figure 2): structured information,
textual comment, and general information.
Structured information
The core element of disease annotation in CIDeR is the
structured information describing the interaction
between two elements as a formal subject-predicate-
object structure (for example, protein A increases_activi-
ty_of protein B). A similar structure is used in resources
(a)
(b)
Figure 2 The CIDeR home page and curation of an interaction. (a) The CIDeR home page contains statistics, search options as well as links
to focus topics and disease pages. (b) A manually curated interaction containing general information, textual information (comment), and
structured information (formal description).
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such as Drugbank [11] or in the process diagram editor
CellDesigner [6]. Subjects and objects can be molecules
such as nucleic acids, proteins or chemical compounds
and other elements like cellular processes, phenotypes
or environmental factors. In order to provide the con-
tent of CIDeR in a standardized format, we use names
and identifiers from established resources like Entrez-
Gene [12], KEGG [5], CORUM [13] or Online Mende-
lian Inheritance in Man (OMIM) [14] for annotation.
The structured information is required for analysis of
the interactions via bioinformatics methods. However, a
caveat of this type of data is that it is restricted to the
basic information of an experiment and thus does not
include important details of the experimental approach
or results.
Textual comment
This kind of information is found in the textual infor-
mation of interactions in CIDeR. It is especially useful
for experimentally working scientists to know at what
concentrations a drug has been applied in an experi-
ment and it is of general interest to know to what
extent the expression of a protein has been increased.
The textual information provides an integrated view
aiming for combining information from different
sources in a comprehensive form.
General information
The general information includes literature references,
the respective disease, and information describing the
experimental setup. This information is required to be
aware whether a finding holds true for all organisms or
only for individuals with a specific genetic or experimen-
tal disposition. For example, there is growing evidence
that the gender has an important role in disease pro-
cesses. For type 2 diabetes it was shown that Gly482Ser
polymorphism of PGC-1alpha (encoded by PPARGC1A)
was associated with a lower plasma adiponectin level in
type 2 diabetic men but not in type 2 diabetic women
[15]. In neurological diseases, gender-specific disease pro-
cesses were also found. XBP1 deficiency in female mutant
SOD1 transgenic mice resulted in a highly significant
increase in life span of 22 days [16].
Interaction data from CIDeR can be downloaded as
flat files or in Systems Biology Markup Language
(SBML), a free and open interchange XML format for
computer models of biological processes [17]. Files in
the SBML format can also be loaded with network ana-
lysis tools such as Cytoscape [18]. Besides downloading
of the complete database, CIDeR also enables download-
ing of interactions from search results. Graphical out-
puts can be downloaded in JPEG format or GraphML
format. The latter can be opened and edited via the
graph editor yED (yWorks GmbH, Tübingen, Germany).
Search options and visualization of interaction
networks
A flexible web-based interface [19] allows both simple
and more advanced searching of CIDeR. The interface
has been developed in close collaboration with experi-
mental biologists to ensure that the interface is intuitive
and easy to use for the end user. In order to allow
defining a precise search space, CIDeR offers various
search options. By default all disease interactions are
queried, but the user has the option to define the search
for only a set of diseases. This is especially useful when
processes from different diseases are interconnected.
Evidence was found that related disease-associated cellu-
lar processes are affected in Alzheimer’s disease and
type 2 diabetes. In the Rotterdam study, it was shown
that diabetes mellitus almost doubled the relative risk of
dementia and Alzheimer’s disease [20].
Complex search and analysis options permit more
powerful systems-level views of the disease relevant pro-
cesses. The options include, among others, the ability to
search for, for example, ‘Gene/Protein/Complex’, ‘Biologi-
cal process’, ‘Tissue/cell line’ or ‘Chemical compound’. To
make this process intuitive, all of the possibilities are listed
in a ‘dropdown box’. Molecule searches allow searching
for a particular gene or chemical compound of interest,
either by name or via identifiers from external databases.
In addition, CIDeR stores lists of all synonyms from Entrez
Gene [12] and KEGG [5]. Gene or chemical compound
searches of CIDeR automatically search all possible alter-
native names for the query rather than restricting searches
to particular names or symbols from a specific database. If
an initial search has been finished, it can be refined with a
second search by using the ‘refine query’ option. Results of
the second search term are associated with the first search
term by one of the three operators ‘AND’, ‘OR’ and ‘NOT’.
The search results appear as a table that links to the
curated content of the interactions or to a graph tool that
dynamically generates a graph from the search results
(Figure 1; Figures s1, s2, s3, and s4 in Additional file 1).
All disease interactions can be interactively investigated
using the yFiles framework (yWorks GmbH) with an
AJAX extension that automatically generates more biolo-
gically intuitive pathway-like layouts of a network. Within
the graph, interactions are shown as color-coded nodes
(in graphs, nodes are objects such as a protein, chemical
compound or bioprocesses) that are linked via defined
relations (edges). The graph tool enables generation of an
optimized layout of the graph elements and also allows
implementation of interactive tools. While moving the
mouse cursor over edges, pop-up windows with respec-
tive interaction information appear (Figure 1). A click on
the edge opens a window with the complete annotated
information about this interaction. Another useful func-
tion is the extension of the graph for an element of
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interest. If the user wants in addition to show all interac-
tions that are linked to a certain node, he just needs to
double-click on the element.
In addition to the ability to generate user-defined
graphs, CIDeR provides predefined graphs (Focus topics)
on the homepage displaying the role of inflammation
and mitochondria for the annotated diseases and conco-
mitantly offering an entry point in order to explore the
structure of disease networks in CIDeR (Figure 2). Here,
additional predefined graphs for disease-relevant sub-
jects like the interconnection between Parkinson’s dis-
ease and cancer are shown. In addition, these pages
offer statistics about proteins, chemical compounds, and
biological processes that are hyperlinked to the respec-
tive content. The generation of novel ‘Focus topics’ is an
ongoing activity that sheds light on current develop-
ments in disease research.
Comparison of CIDeR with existing resources
An early example of an effort to display biological pro-
cesses in graphical networks is the biochemical pathways
from Gerhard Michal [21]. Despite several resources
such as Reactome [22] and PharmGKB [23] that present
biochemical pathways in network structure, there are
only few approaches providing disease information in a
network structure. Two notable, publicly available exam-
ples are KEGG pathways [5] and process diagrams con-
structed with CellDesigner [24]. The conceptual
approach of CIDeR offers advantages compared to dis-
ease information from KEGG and CellDesigner. First,
CIDeR is an extensive, manually curated resource that
mostly provides direct experimental evidence for the
interactions and also associated context information.
Disease information in KEGG is also collected by man-
ual curation but is mainly based on review information.
As a result, biomedical information in CIDeR provides
results from investigations in more depth and, in addi-
tion, CIDeR presents important context information
such as cell lines and gender of organisms. Second, in
contrast to KEGG and CellDesigner, CIDeR offers mul-
tiple search options enabling specific areas of diseases to
be focused on and the results to be presented in dyna-
mically generated graphs. Graphical representation in
KEGG and CellDesigner is static and shows the com-
plete disease information in a single diagram. Static dia-
grams are useful for presentation of the scientific
progress at the time of creation. However, inclusion of
novel findings into complex process diagrams like in
CellDesigner is hardly feasible. Third, disease informa-
tion in CellDesigner and especially KEGG is limited to
the basic concepts of diseases. The type 2 diabetes dia-
gram in KEGG [5] consists of 36 interactions whereas
CIDeR currently presents 6,911 interactions for the dis-
ease. The limited amount of data in KEGG is a result of
the static diagrams, as these become hardly comprehen-
sible if a large amount of details has to be shown.
Fourth, CIDeR includes a wide range of disease-relevant
molecules as well as other disease relevant factors such
as bioprocesses and phenotypes. Disease annotation in
KEGG and CellDesigner is concentrated on interactions
between proteins. An extension of the KEGG dataset is
available from the PROMISCOUS database [25] that
includes the protein-drug interactions from Drugbank
[11]. Fifth, information from CIDeR can be downloaded
(see below) as a complete database but also areas of
interest that are generated by searches. Download in
KEGG always includes the complete dataset. Users that
are interested in a particular aspect of the disease have
to sort out the respective interactions manually.
A further resource providing manually curated disease
interactions is the Comparative Toxicogenomics Data-
base (CTD). CTD provides a manually curated triad of
chemical-gene, chemical-disease and gene-disease rela-
tionships from the literature [26]. For these three types
of interactions, CTD provides 260,300 data points cover-
ing a large variety of diseases. The conceptual difference
between the two resources is that CTD stores a large
number of valuable interactions whereas CIDeR adopts
a disease process-oriented approach and facilitates the
inspection of interconnected disease networks. There-
fore, the description of the pathobiological processes for
this complex disease in CIDeR requires at least 40 dif-
ferent types of interactions (see below). As a conse-
quence of the process-driven approach CIDeR enables
interactive visualization of disease-networks, which is
not available for CTD. In addition, CIDeR provides a
more in-depth annotation including contextual informa-
tion as described above.
The quantitative comparison reveals that the different
approaches of CIDeR, KEGG, CTD and CellDesigner
result in significant differences with respect to the vari-
ety and absolute numbers of interactions (Tables s1, s2,
s3, and s4 in Additional file 2). Metabolic syndrome/
type 2 diabetes is a disorder that is covered by all four
resources. KEGG, which covers a large spectrum of dif-
ferent bioprocesses and diseases, uses 36 interactions
and two different interaction types (gene-gene and gene-
chemical compound) in order to annotate type 2 dia-
betes. The CTD database provides a total of 21,791
interactions distributed on two interaction types (chemi-
cal-disease and gene-disease) for diabetes type 2. The
chemical-compound gene interactions from CTD could
not be included in the statistical comparison as they are
not assigned to defined diseases and are, to some extent,
not disease-associated at all. Annotation of metabolic
syndrome in SBML format [17] with diagrams created
using CellDesigner make use of eight different interac-
tion types and 97 interactions. For annotation of
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diabetes/metabolic syndrome in CIDeR we have cur-
rently annotated 7,165 disease-interactions that are
found in 40 different interaction types. In conclusion,
the quantitative analysis of the different resources
results in few interactions for the general overview given
in KEGG, an extensive set of data restricted to two dis-
ease interaction types in CTD and a large number of
different interaction types for the network-oriented
approach in CIDeR.
A large fraction of other disease-related resources is
dedicated to particular diseases or specific molecules.
SZgene provides a field synopsis of genetic association
studies in schizophrenia [27], dbDEPC is a database of
differentially expressed proteins in human cancers [28]
and MDPD is a mutation database for Parkinson’s disease
[29]. All these databases contain invaluable information
for disease research but they do not support approaches
in the fields of systems biology and network medicine.
Applications of the CIDeR database
The aim of CIDeR is to provide a knowledge resource
for experimentally working scientists as well as to pre-
sent structured information for systems biology and ana-
lyses of high-throughput experiments. In-depth manual
annotation of scientific literature offers wet-lab scientists
a substantial structured overview about disease pro-
cesses. This information is highly suitable to generate
qualitative models and hypotheses to be tested experi-
mentally. Especially the simultaneous inspection of
results within a disease area such as neurological dis-
eases overcomes the limits of intuitive but inefficient
trial and error approaches. An example of the benefit
that can be derived from comparing different research
fields is the mood stabilizer lithium (Figure 1), a psy-
chiatric drug that has been the standard pharmacologi-
cal treatment for bipolar disorder for many years [30].
In a recent study it was found that daily doses of lithium
delay disease progression in human patients affected by
ALS [31]. In the same study a neuroprotective effect of
lithium could be demonstrated, which is well in line
with the observation that lithium has neurotrophic
effects in bipolar disorder [32].
Inspection of a disease network can reveal the multi-
ple interactors of lithium, such as glycogen synthase
kinase-3 (GSK3), calreticulin or the heat shock protein
HSPA5, which are proposed to mediate lithium action.
If lithium delays disease progression in human patients
affected by ALS according to [31] and lithium directly
interacts with GSK3, calreticulin and HSP5, the expres-
sion of the genes encoding these three proteins might
serve as an indicator of disease development (Figure 1).
Information about different diseases in CIDeR also
allows detection of potential side effects of drugs, such
as adverse reactions. HSD11B1 (11-beta hydroxysteroid
dehydrogenase type 1) catalyzes the conversion of inac-
tive cortisone to active cortisol. The discovery that
increased cortisol levels are involved in the etiology of
metabolic syndrome and type 2 diabetes gave rise to the
development of the HSD11B1 inhibitors INCB13739
and MK-0916 [33,34]. Since polymorphisms in the
HSD11B1 gene have been associated with increased risk
for Alzheimer’s disease [35] and susceptibility to inci-
dent depression [36], HSD11B1 inhibitors should speci-
fically be tested for their effects in patients affected by
Alzheimer’s disease or depression (Additional file 3).
Systems biology represents a general integrative strategy
for the understanding of complex biological systems [37].
Currently, approaches exist that allow dynamic modeling
- for example, of T-cell receptor signaling, with 94 nodes
[38]. The first step in modeling is construction of a quali-
tative network describing the mode of interaction
between the components of a network. Inclusion of
experimental data subsequently enables the design of
quantitative models allowing for a parameterized predic-
tion of observable readouts leading to a deeper under-
standing of perturbed molecular mechanisms in disease
processes. Due to the structured annotation of the CIDeR
content, the dataset is well suited to construct qualitative
disease networks on a rational basis while saving time
and effort for extensive literature research.
To expedite the molecular elucidation of human dis-
eases, we will face an avalanche of data from genome
sequencing and exome sequencing experiments in the
years to come [39]. The challenge for the interpretation
of high-throughput -omics data lies in assimilating it in
the context of existing knowledge. Currently, this step is
often restricted to Gene Ontology [40] enrichment ana-
lysis, allowing only very general but intuitive conclu-
sions. As an example beyond mapping to functional
categories, a recent study for autosomal-recessive intel-
lectual disability has revealed probable disease-causing
variants in 50 novel candidate genes [4]. With the help
of protein-network analysis it could be shown that novel
candidate genes are within functional interaction net-
works together with previously known intellectual dis-
ability genes. For such network-oriented approaches
CIDeR can be useful as it interconnects proteins not
only by protein-protein interactions but also by linking
proteins via factors such as microRNAs, chemical com-
pounds, bioprocesses, and environmental factors.
In conclusion, CIDeR provides a publicly available
integrative resource for researchers in neurological and
metabolic diseases as well as for the broader life science
community. CIDeR has been developed to present biolo-
gical facts in an intuitively displayed molecular interac-
tion network and pathway context, which will enable
scientists without a strong computational background to
explore their data in a more systems-oriented manner.
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Additional material
Additional file 1: Supplementary figures. Figure s1: Go to the CIDeR
homepage: Focus topics in diseases => mitochondria. Choose ‘Mental
disorders’ and click on ‘Graph’. A user who is interested in a research
area, such as mitochondria, that is prepared as focus topic has access to
this information via links on the CIDeR homepage. In order to obtain
more or more specific information on the topic, the user has the option
to start an individual search (Figure s2). Figure s2: CIDeR query:
mitochondrial respiratory chain complex V. The user starts a survey in
CIDeR - for example, with a query for ‘Mitochondrial respiratory chain
complex V’ - and clicks on ‘Graphical View’. Knowledge of the precise
term is not required as CIDeR makes use of an auto-complementation
tool that offers all related terms in the database after a few characters
have been filled in. The search for ‘Mitochondrial respiratory chain
complex V’ results in a graph consisting of six elements (nodes). It shows
that the mitochondrial respiratory chain complex V is linked to bipolar
disorder as well as to two angiotensin receptors (AGTR1 and AGTR2),
which are all part of the angiotensin-renin system, which regulates blood
pressure but also interacts with insulin signaling and is thus part of the
type 2 diabetes network. A double-click on AGTR1 (Figure s3) extends
the ‘Mitochondrial respiratory chain complex V’ for the AGTR1 network.
Figure s3: CIDeR query: Mitochondrial respiratory chain complex V and
double-click on AGTR1. A double-click on AGTR1 shows relations
between AGTR1 and several drugs - for instance, nebivolol, a beta-
blocker. Nebivolol interacts with a number of proteins and processes,
many of them involved in blood pressure regulation, but also insulin
resistance. AGTR1 also shows an interaction with cortisol (Figure s4).
Figure s4: CIDeR query: Mitochondrial respiratory chain complex V and
double-click on AGTR1 and double-click on cortisol. A double click on
cortisol leads to interactions with different diseases (Alzheimer’s disease,
schizophrenia, insulin resistance) as well as to inflammatory response, a
bioprocess that is involved in the etiology of various diseases and is also
curated in CIDeR as ‘Focus topic’. The figure shows that different
diseases, such as bipolar disorder and insulin resistance, can be linked via
a few elements (’Mitochondrial respiratory chain complex V’-AGTR1-
cortisol) and that a disease network is created that can facilitate the
generation of hypotheses - for example, to investigate diseases using
drugs that are not ordinarily used for them.
Additional file 2: Supplementary tables. Table s1: quantitative
comparison of interaction information in different resources - diabetes/
metabolic syndrome. The table shows the different types of interactions
(process-phenotype, environment-process, microRNA-genes, and so on)
and the number of respective interactions for diabetes/metabolic
syndrome. Table s2: quantitative comparison of interaction information in
different resources - Alzheimer’s disease. The table shows the different
types of interactions (process-phenotype, environment-process,
microRNA-genes, and so on) and the number of respective interactions
for Alzheimer’s disease. Table s3: quantitative comparison of interaction
information in different resources - Parkinson’s disease. The table shows
the different types of interactions (process-phenotype, environment-
process, microRNA-genes, and so on) and the number of respective
interactions for Parkinson’s disease. Table s4: quantitative comparison of
interaction information in different resources - amyotrophic lateral
sclerosis. The table shows the different types of interactions (process-
phenotype, environment-process, microRNA-genes, and so on) and the
number of respective interactions for amyotrophic lateral sclerosis.
Additional file 3: Potential side effects of type 2 diabetes drugs on
patients affected by Alzheimer’s disease or depression.
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